Annovis Bio Inc (ANVS)

Over the past six months, Annovis Bio's stock price has fluctuated and as of February 7, 2026, the stock was trading at $2.49, with a 6-month change of -2.35%. In August 2025, the company reported second-quarter financial results and provided a business update. In October 2025, Annovis Bio announced encouraging biomarker results from its Phase 2/3 AD trial and completed registered direct offerings, raising $6.0 million and $3.4 million, respectively. On November 12, 2025, Annovis Bio provided corporate updates and reported third-quarter 2025 financial results. On December 18, 2025, the company announced an open-label extension study for Parkinson's disease patients. On January 28, 2026, Annovis Bio hosted a corporate update webinar.

As a clinical-stage pharmaceutical company, Annovis Bio, Inc. does not currently have commercialized products or services that generate revenue, therefore, traditional demand seasonality is not applicable. Its financial health and market perception are instead driven by research and development progress, clinical trial results, and financing activities.

Annovis Bio, Inc. is a clinical-stage pharmaceutical company focused on developing drugs for neurodegenerative diseases like Alzheimer's and Parkinson's. Their lead compound, Buntanetap, is in Phase 3 trials for Alzheimer's and Parkinson's diseases and Phase 2/3 trials for Lewy Body Dementia, aiming to restore nerve cell function. ANVS405, an intravenous formulation of Buntanetap, is being developed for acute neurodegeneration, specifically TBI and stroke. ANVS301, an orally administered drug, has completed Phase 1 trials and is intended to enhance cognitive capabilities in later stages of Alzheimer's and dementia. As a clinical-stage company, Annovis Bio currently generates no revenue.

Annovis Bio, Inc. is headquartered in Berwyn, Pennsylvania, and primarily conducts its drug development activities in the United States. Its pivotal Phase 3 Alzheimer's study has all 84 clinical sites fully activated and enrolling patients across the U.S.

Annovis Bio's brand reputation has been influenced by its clinical trial progress and financial standing. In March 2025, Annovis Bio received a notice from the NYSE indicating non-compliance with continued listing standards. In April 2024, the release of data from its completed Phase 2/3 AD study led to a nearly 70% decrease in stock price. In October 2025, the announcement of encouraging biomarker results from its Phase 2/3 AD trial likely had a positive impact. The company has been actively strengthening its intellectual property, securing global IP protection through 2046.

Individual investors constitute the largest shareholder group in Annovis Bio, Inc., holding 59% ownership of the company, while insiders collectively own 31% of the shares. Michael M. Hoffman owns 17% of shares outstanding, and Maria Maccecchini owns 12% of common stock. Vanguard Group Inc. held 923,201 shares as of December 31, 2025.